P47 Re-treatment with filgotinib in patients with ulcerative colitis following treatment interruption: SELECTION and SELECTIONLTE data

IntroductionLong-term treatment regimens for UC present challenges for patients who may need to interrupt therapy. Filgotinib (FIL) is an oral JAK1 preferential inhibitor. We performed a post hoc analysis of data from patients treated with FIL in the phase 2b/3 SELECTION programme to assess the effi...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Gut 2022-06, Vol.71 (Suppl 1), p.A61-A62
Hauptverfasser:	Morison, Ben, Vermiere, Severine, Feagan, Brian, Peyrin-Biroulet, Laurent, Oortwijn, Alessandra, Faes, Margaux, Haas, Angela de, Rogler, Gerhard
Format:	Artikel
Sprache:	eng
Schlagworte:	Disease control Janus kinase Patients Poster presentations Remission Remission (Medicine) Ulcerative colitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!